Patents by Inventor Chris Knight

Chris Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Solar Canopy Assembly Tooling, Method of Assembling a Solar Canopy and a Solar Canopy
    Publication number: 20160190974
    Abstract: Methods and apparatus for assembling solar canopy subassemblies, and solar canopies formed with such solar canopy subassemblies, are provided. The provided method and solar canopy assembly tooling permit solar canopies to be erected quickly and in a highly efficient and cost-effective manner with high quality solar canopy subassemblies, while simultaneously minimizing hazards to solar canopy erection workers by minimizing the amount of time workers must spend at elevated heights and minimizing the number of workers that may be exposed to hazards of associated with elevated work.
    Type: Application
    Filed: December 30, 2014
    Publication date: June 30, 2016
    Inventors: Matthew DICKEY, Robert GARDNER, Chris KNIGHT, Simon MUIR, William C. POULIN, Justin RIDER
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20150139916
    Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio RANCATI, Ian Linney, Chris Knight, Wolfgang Schmidt
  • 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(SIP)receptors
    Patent number: 9029405
    Abstract: The present invention provides compounds of Formula (I), as selective S1P1 inhibitors, as well as their use for treating multiple sclerosis and other diseases.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: May 12, 2015
    Assignee: Merck Serono S.A.
    Inventors: Agnes Bombrun, Anna Quattropani, Jerome Gonzalez, Jerome Dorbais, Chris Knight, Charles Baker-Glenn
  • Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
    Patent number: 9012644
    Abstract: Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 21, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Fabio Rancati, Andrea Rizzi, Ian Linney, Wesley Blackaby, Chris Knight
  • Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
    Patent number: 8980913
    Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 17, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Fabio Rancati, Ian Linney, Chris Knight, Wolfgang Schmidt
  • Pyrazole oxadiazole derivatives as S1Pagonists
    Patent number: 8802663
    Abstract: The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R1, R2 and R3 are as defined in the description.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: August 12, 2014
    Assignee: Merck Serono SA
    Inventors: Anna Quattropani, Charles Baker-Glenn, Wesley Blackaby, Chris Knight
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20140163066
    Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Application
    Filed: December 6, 2013
    Publication date: June 12, 2014
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Fabio RANCATI, Ian Linney, Chris Knight, Wolfgang Schmidt
  • 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS
    Publication number: 20130116289
    Abstract: The present invention provides compounds of Formula (I), as selective S1P1 inhibitors, as well as their use for treating multiple sclerosis and other diseases.
    Type: Application
    Filed: July 6, 2011
    Publication date: May 9, 2013
    Applicant: MERCK SERONO S.A.
    Inventors: Agnes Bombrun, Anna Quattropani, Jerome Gonzalez, Jerome Dorbais, Chris Knight, Charles Baker-Glenn
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20130034504
    Abstract: Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.
    Type: Application
    Filed: June 8, 2012
    Publication date: February 7, 2013
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Fabio RANCATI, Andrea Rizzi, Ian Linney, Wesley Blackaby, Chris Knight
  • Triazole oxadiazoles derivatives
    Patent number: 8202856
    Abstract: The invention relates to compounds of formula I: wherein R1, R2,Ra, Rb, X have the meanings given in claim 16. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: June 19, 2012
    Assignee: Merck Serono SA
    Inventors: Anna Quattropani, Christophe Cleva, Eric Sebille, Matthias Schwarz, Delphine Marin, Agnes Bombrun, Wesley Blackaby, Charles Baker-Glenn, Chris Knight, Craig Rouse
  • PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS
    Publication number: 20120071460
    Abstract: The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R1, R2 and R3 are as defined in the description.
    Type: Application
    Filed: June 7, 2010
    Publication date: March 22, 2012
    Applicant: MERCK SERONO SA
    Inventors: Anna Quattropani, Charles Baker-Glenn, Wesley Blackaby, Chris Knight